Investigating neurotransmission pathways in Neurodegenerative diseases
Tocris Biosciences enables researchers to study the impacts of neurotransmitters with a wide range of chemical inhibitors and antagonists. The use of small molecule inhibitors and antagonists to facilitate neurotransmission research has helped delineate the pathways involved in many neurodegenerative diseases, as well as providing a solid foundation for the development of future targeted therapeutics. Tocris provides an innovative range of high performance life science reagents for use in neurodegeneration research, equipping researchers with selective pharmacological tools for studying these disease pathways.
|
Tocris Product Name |
Activity |
Details |
Key Research Area |
|---|---|---|---|
|
Potent and selective CB2 receptor inverse agonist |
Orally bioavailable |
Alzheimer’s disease |
|
|
Potent and selective GPR139 agonist |
Orally bioavailable and brain penetrant |
Neuroscience |
|
|
Potent and selective MTORC1/2 inhibitor (IC50 = 1.5 nM) |
Orally available |
Alzheimer’s disease |
|
|
Potent γ-secretase inhibitor (IC50 = 1.2 nM) |
Reduces Amyloid β levels in the brains of mice |
Alzheimer’s disease |
|
|
Selective inhibitor of presynaptic choline transporters (CHTs) |
CHTs transport choline into presynaptic neurons for the synthesis of acetylcholine (a neurotransmitter) |
Neuroscience |
|
|
Potent and selective bromodomain (BRD) 7/9 inhibitor |
BRDs are regions of certain proteins that bind to histones adjacent to DNA, enabling the protein to influence gene expression. Cell permeable and orally active. |
Multiple sclerosis |
|
|
Potent and selective sphingosine phosphate receptor S1P5 agonist |
Reverses age-related cognitive decline in mice |
Neurodegeneration |
Launched in July 2016 an international consortium of researchers is looking to revolutionise 
